TD Cowen lowered the firm’s price target on Avantor (AVTR) to $12 from $14 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies “already soft guided” 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Avantor downgraded to In Line from Outperform at Evercore ISI
- Avantor appoints Simon Dingemans to board of directors
- Avantor downgraded to Underperform from Hold at Jefferies
- BofA shakes up ratings in Biopharma Services with seven changes